At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,115 enrolled
Drug / intervention
Therapeuticother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The National Myelodysplastic Syndromes Natural History Study
National Heart, Lung, and Blood Institute (NHLBI)·observational·Posted May 17, 2016·Updated Feb 3, 2026
In Brief
An observational study evaluating Therapeutic for Myelodysplastic Syndromes (MDS). Completed, enrolled 2,115 participants across 281 sites in 2 countries.
Detailed Summary
Multi-center study enrolling patients suspected or newly diagnosed with myelodysplastic syndromes (MDS), myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) overlap disorder, or idiopathic cytopenia of undetermined significance (ICUS). Participants will be followed long term. Clinical data, blood, and tissue samples will be collected to establish a biorepository to facilitate the study of the natural history of MDS.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMyelodysplastic Syndromes (MDS)
CountriesIsrael, United States
CollaboratorsNational Cancer Institute (NCI)
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2016
Enrollment StartJun 2016
Primary CompletionJul 2025
Study CompletionDec 2025
TodayJul 2026
First PostedMay 17, 2016
Enrollment StartJun 13, 2016
Primary CompletionJul 31, 2025
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 9.1 yearsPosted 10.1 years ago
Interventions
Therapeuticother
Observational Study